Product Specifications
- Active Ingredient: Hyaluronic acid (cross-linked) 24mg/g; Mannitol 9mg/mL
- Regulatory Status: CE-marked (EU); practitioners should verify current US FDA status and other applicable jurisdictions independently
- Molecular Type: Cross-linked hyaluronic acid (IPN-Like Technology™)
- Strength: 24mg/g HA | 9mg/mL Mannitol
- Dosage Form: Injectable gel — 2 × 1mL prefilled syringes + 4 × 27G ½ needles
- Manufacturer: Laboratories VIVACY
- Brand: STYLAGE®
- Country of Origin: France
- Storage Requirements: Store below 25°C; do not freeze; protect from direct sunlight
- Intended Use: Versatile deep wrinkle correction and volume restoration — for licensed aesthetic professionals
Who Is STYLAGE® L BI-FLEX® Indicated For?
STYLAGE® L BI-FLEX® is formulated for licensed professionals performing advanced aesthetic medicine procedures requiring both wrinkle correction and moderate facial volumization. Also known as BI-soft, the product is recognized for its versatile rheological profile, allowing practitioners to tailor injection depth and technique to the treatment area and the patient’s skin condition.
Common indications include:
- Deep wrinkle correction
- Nasolabial folds
- Marionette lines
- Perioral rhytids
- Glabellar lines
- Midface volume loss
- Chin augmentation support
- Jawline contouring
The filler may be injected into the mid-to-deep dermis or subcutaneous plane, depending on the anatomical region and desired outcome. Factors such as skin type, age-related tissue laxity, and the degree of volume loss should be evaluated before treatment planning.
Many practitioners consider STYLAGE® a good filler because its IPN-Like Technology™ improves cohesivity and elasticity while mannitol helps reduce oxidative degradation. This combination may contribute to longer-lasting correction compared with some conventional injectable dermal fillers. Additionally, the absence of lidocaine allows clinicians to select separate anesthetic approaches based on patient tolerance and procedural preference.
STYLAGE® products are CE-marked for use within the European Union. However, practitioners should verify current regulatory standing in the United States and other jurisdictions before procurement or clinical use. STYLAGE® L BI-FLEX® injection is intended exclusively for trained medical professionals and should never be self-administered.
How Does STYLAGE® L BI-FLEX® Work?
STYLAGE® L BI-FLEX® works through cross-linked hyaluronic acid that integrates into dermal tissue and binds water molecules, creating immediate volumizing and wrinkle-filling effects. The hydrophilic nature of hyaluronic acid contributes to tissue hydration and structural support in targeted treatment areas.
A distinguishing feature of the STYLAGE® filler range is IPN-Like Technology™, which incorporates two interlocked hyaluronic acid polymer networks. This structure enhances cohesivity, elasticity, and resistance to mechanical deformation compared with certain single-network fillers, supporting smoother integration and consistent projection across dynamic facial zones.
The formulation also includes 9mg/mL mannitol, a free radical scavenger intended to inhibit oxidative degradation of hyaluronic acid after implantation. By reducing free radical activity, mannitol may help preserve filler integrity and extend clinical longevity.
Unlike some injectable dermal fillers, STYLAGE® L BI-FLEX® does not contain co-formulated lidocaine. Anesthesia management is therefore performed separately through topical, local, or regional techniques chosen by the practitioner. The product remains fully reversible with hyaluronidase if correction, adjustment, or emergency dissolution becomes necessary.
How Is STYLAGE® L BI-FLEX® Administered, and What Are the Safety Considerations?
STYLAGE® L BI-FLEX® injection should only be performed by qualified aesthetic professionals familiar with facial anatomy, vascular safety protocols, and complication management. Recommended injection depth varies according to the treatment area and clinical indication. Common techniques include linear threading, fanning, cross-hatching, and serial puncture. Injection may be placed in the mid-to-deep dermis or the subcutaneous layer, depending on correction goals and tissue thickness. Because the product contains no lidocaine, practitioners should apply topical or local anesthesia separately before treatment where appropriate.
After treatment, patients should avoid excessive sun exposure, intense heat, and strenuous exercise until redness and swelling resolve. Bruising at the injection site may occur and typically resolves within a few days.
Common Side Effects
Most side effects are transient, localized, and self-limiting. Common reactions include redness, swelling, tenderness, bruising, mild discomfort, and temporary firmness at the injection site. These effects generally resolve within a few days following treatment.
Serious Adverse Events
Although uncommon, serious complications may occur with all injectable dermal fillers, including vascular occlusion, skin necrosis, infection, delayed inflammatory reactions, and visual disturbances. Immediate recognition and intervention are essential. Practitioners should maintain emergency protocols and access to hyaluronidase during treatment sessions.
Patients with known hypersensitivity to hyaluronic acid products or active skin infections at the intended injection site should not receive treatment. Clinicians should consult the official Instructions for Use (IFU) for complete contraindication and safety guidance. Practitioners sourcing the product should evaluate supplier authenticity, cold-chain integrity, and distributor compliance to help minimize risks associated with counterfeit or improperly stored products.
What Is the Regulatory Status of STYLAGE® L BI-FLEX®?
STYLAGE® L BI-FLEX® is manufactured in France by Laboratories VIVACY and carries CE marking for professional aesthetic use within applicable European markets. The product is restricted to licensed medical professionals and registered aesthetic clinics trained in injectable procedures. Regulatory requirements may differ across jurisdictions, and practitioners should independently verify local approval and import regulations before clinical use. Current US FDA status and regional regulatory standing should be confirmed before administration.
Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact Medical Spa Rx’s professional support team for sourcing information and documentation support. Regulatory information is current as of May 2026; practitioners should verify local requirements before procurement or use. For sourcing guidance, contact Medical Spa Rx’s professional support team.
